Lupus Anticoagulant Test Kits
Both LA-Screen and LA-Confirm are simplified Dilute Russell's Viper Venom Time Tests (DRVVT) used for the detection of Lupus Anticoagulants (LA) in one stage clotting tests. Both products are sold as lyophilized reagents and are available in both a small and large size format.
LA-Screen 10 (10 x 2ml vials) Cat# LASD-10
LA-Screen 25 (10 x 5ml vials) Cat# LASD-25
LA-Confirm 5 (10 x 1ml vials) Cat# LACD-5
LA-Confirm 10 (10 x 2ml vials) Cat# LACD-10
LAs are autoantibodies against negatively charged phospholipids or complexes of phospholipids with either beta-2-glycoprotein 1 or clotting factors such as prothrombin. They occur in various clinical conditions, especially autoimmune diseases and are now considered to be a significant risk factor in patients with otherwise unexplained thrombosis and are often present in women who have recurrent foetal loss. LA have traditionally been detected using phospholipid responsive clotting tests, such as the activated partial thromboplastin time (APTT), kaolin clotting time (KCT) and DRVVT where they have an anticoagulant effect. The DRVV time first became popular following the publication by Thiagarajan et al. in 1986. Gradipore/DSRV Inc has simplified and standardized this method. According to Petri et al, thrombosis in SLE patients is more closely linked with LA detectable by DRVVT than with anticardiolipin antibodies detected by enzyme linked immunosorbent assays (ELISA). This observation was recently extended by Galli and Bevers who showed that the LA subtype with most effect on DRVVT tests is beta-2-glycoprotein 1 dependent and different to the prothrombin-requiring LA subtype having more prolonging effect on KCT tests.
Specialty kits & reagents
Collagen Binding Assay ELISA Kits
Enzyme immunoassay for the determination of von Willebrand Factor (VWF) function in human plasma. The Collagen Binding Assay (CBA) can be used to differentiate between von Willebrand Disorder (VWD) Type I and Type II when used in conjunction with the VWF antigen (VWF:Ag) assay.
VWF is an important blood clotting protein, involved in both assisting platelet adhesion and stabilization of clotting factor VIII. In von Willebrand Disease (VWD) there is typically a partial quantitative deficiency (classified as VWD Type 1) or a qualitative deficiency (classified as VWD Type 2). VWD Type 3 is rare and characterised by virtually complete deficiency of VWF. Higher molecular weight multimers of VWF serve to bind activated platelets through specific membrane glycoproteins to connective tissue fibres exposed at wound sites and thus promote blood clotting and wound sealing2. The incidence of VWD worldwide is estimated at 1% to 3% but may be more common as mild cases may remain undetected. The CBA is an ELISA procedure that quantitates the collagen binding capacity (VWF:CB) of VWF to collagen coated microtitre wells. Collagen binding of VWF is associated with the higher molecular weight (HMW) forms of VWF, believed to be functionally more important in haemostasis than lower molecular weight forms (LMW). Therefore CBA may correlate more closely with VWF function and bleeding problems than regular ELISAs for VWF which measures total (LMW + HMW) VWF.
Collagen Binding Assay ELISA kit (1x96 well Elisa Kit) Cat# CBAE-1